IP Library › Granted Patent US 10,238,697
Granted Patent B2
US 10,238,697 · App. 15/565,958 · Granted Mar 26, 2019

Lactococcus lactis producing TSLP or IL-25 and their uses as probiotics and therapeutics

Inventors: Philippe Langella (Velizy, FR); Jean-Marc Chatel (Meudon, FR); Luis Bermudez-Humaran (Jouy-en-Josas, FR); Camille Aubry (Saint-Germain-en-Laye, FR); Laurence Goffin (Ornex, FR); Simone Favre-Zimmerli (Burlington, MA); Yolande Chvatchko (Confignon, CH)
Assignee: ARES TRADING S.A.
A61K35/744A23L33/135A23L33/30A61K38/19A61K38/20A61K45/06A61P1/00A61P1/04A61P29/00A61P37/02C07K14/315C07K14/52C07K14/54C12N15/746A23V2002/00A23Y2240/41A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,697
App. No.
15/565,958
Granted
Mar 26, 2019
Kind
B2
Abstract

The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.

Claims (8)

1. A recombinant Lactococcus lactis bacterium, wherein the bacterium comprises an expression cassette comprising a heterologous nucleotide sequence encoding a cytokine selected from the group consisting of thymic stromal lymphopoietin (TSLP) and interleukin-25 (IL-25), wherein the heterologous nucleotide sequence encoding the cytokine is under the control of a promoter of the GroESL operon of Lactococcus lactis.

2. The recombinant Lactococcus lactis bacterium according to claim 1 , wherein the expression cassette further comprises a nucleotide sequence encoding an extracellular addressing peptide.

3. The recombinant Lactococcus lactis bacterium according to claim 1 , wherein the TSLP is human TSLP.

4. The recombinant Lactococcus lactis bacterium according to claim 1 , wherein the IL-25 is human IL-25.

5. A pharmaceutical or probiotic composition comprising a recombinant Lactococcus lactis bacterium according to claim 1 .

6. The pharmaceutical or probiotic composition according to claim 5 , wherein the composition comprises a recombinant Lactococcus lactis bacterium secreting TLSP and/or a recombinant Lactococcus lactis bacterium secreting IL-25.

7. The pharmaceutical or probiotic composition according to claim 5 , the composition further comprising an anti-inflammatory or immune-modulatory drug.

8. A food composition comprising a recombinant Lactococcus lactis bacterium according to claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2018
From: LANGELLA, PHILIPPE; CHATEL, JEAN-MARC; BERMUDEZ-HUMARAN, LUIS; AUBRY, CAMILLE; GOFFIN, LAURENCE; FAVRE-ZIMMERLI, SIMONE; CHVATCHKO, YOLANDE
To: ARES TRADING S.A.
Reel/Frame 047814/0016 →
Priority Claims (1)
EP 15163637 · Apr 15, 2015 · regional
Continuity (1)
Related Publication 20180104285A1 · Apr 19, 2018
Cited By (1)
US 12,247,071